Seres Therapeutics, Inc.
Datakwaliteit: 100%
MCRB
NASDAQ
Manufacturing
Chemicals
€ 8,85
▲
€ 0,02
(0,23%)
6 months return
—
Momentum
Neutral
5Y revenue growth
-72,84%
Groei
Revenue Growth (5Y)
-72,84%
Onder sectorgemiddelde (1,72%)
Revenue (1Y)N/A
Earnings (1Y)4088,24%
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
14,86%
Boven sectorgemiddelde (-54,68%)
ROIC-63,48%
Net Margin721,93%
Op. Margin-11910,14%
Veiligheid
Debt / Equity
N/A
Current Ratio2,30
Interest CoverageN/A
Waardering
PE (TTM|NTM)
14,92 | -0,96
Boven sectorgemiddelde (-1,49)
P/B Ratio1,94
EV/EBITDAN/A
Dividend YieldN/A
Quick Summary
Key Takeaways
Short bullets derived from reported financials—not the AI summary above.
Revenue declined -72,84% annually over 5 years
Earnings grew 4088,24% over the past year
ROE of 14,86% — decent returns on equity
Net margin of 721,93% shows strong profitability
Generating 865.000,0 in free cash flow
P/E of 14,92 — trading at a low valuation
Price History
Financiële Trends
Koersdoel Analisten
1 analist
Buy
+148.6%
upside to target
Huidig
€ 8,85
Consensus Target
€ 22,00
€ 22,00
Laag
€ 22,00
Hoog
Vooruitzicht
Forward K/W
-0,96
Forward WPA
-€ 9,17
Omzet Sch.
0,0
Winstverassingen
EPS
Reported
Estimate
Forecast
Next: Q1 2026
·
EPS Est: -€ 1,88
·
Rev Est: 0,0
| Q12025 | Q22025 | Q32025 | Q42025 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|---|---|
| Reported | -€ 2,24 | -€ 2,27 | € 0,94 | -€ 1,76 | — | — |
| Estimate | € 1,97 | -€ 2,28 | € 1,28 | -€ 1,60 | -€ 1,88 | -€ 2,11 |
| Verrassing | -213,57% | +0,22% | -26,56% | -10,00% | — | — |
Growth
Rev 5Y: -72,84% · Earnings 1Y: 4088,24%
Growth
Rev 5Y: -72,84% · Earnings 1Y: 4088,24%| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | -92,10% |
| Earnings Growth (1Y) | 4088,24% | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | -72,84% | Earnings Growth (5Y) | N/A |
Profitability
ROE: 14,86% · Net Margin: 721,93%
Profitability
ROE: 14,86% · Net Margin: 721,93%| Revenue (TTM) | 789.000,0 | Net Income (TTM) | 5,70 M |
| ROE | 14,86% | ROA | 3,97% |
| Gross Margin | N/A | Operating Margin | -11910,14% |
| Net Margin | 721,93% | Free Cash Flow (TTM) | 865.000,0 |
| ROIC | -63,48% | FCF Growth (3Y) | N/A |
Safety
D/E: N/A · Current: 2,30
Safety
D/E: N/A · Current: 2,30| Debt / Equity | N/A | Current Ratio | 2,30 |
| Interest Coverage | N/A | Asset Turnover | 0,01 |
| Working Capital | 29,10 M | Tangible Book Value | 43,70 M |
Dividends
Yield: N/A · Payout: N/A
Dividends
Yield: N/A · Payout: N/A| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
Valuation
P/E: 14,92 · EV/EBITDA: N/A
Valuation
P/E: 14,92 · EV/EBITDA: N/A| P/E Ratio | 14,92 | Forward P/E | -0,96 |
| P/B Ratio | 1,94 | P/S Ratio | 107,71 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | 1,02% | ||
| Market Cap | 84,98 M | Enterprise Value | 37,34 M |
Per Share
EPS: 0,64 · FCF/Share: 0,09
Per Share
EPS: 0,64 · FCF/Share: 0,09| EPS (Diluted TTM) | 0,64 | Revenue / Share | 0,08 |
| FCF / Share | 0,09 | OCF / Share | 0,12 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
Efficiency
FCF Conv: 15,19% · CapEx/Rev: 31,94%
Efficiency
FCF Conv: 15,19% · CapEx/Rev: 31,94%| CapEx / Revenue | 31,94% | FCF Conversion | 15,19% |
| SBC-Adj. FCF | -11,96 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 789.000,0 | — | 126,33 M | 7,13 M | 144,93 M |
| Net Income | 5,70 M | 136.000,0 | -113,72 M | -250,16 M | -65,58 M |
| EPS (Diluted) | 0,64 | 0,00 | -0,89 | -2,31 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -93,97 M | -121,32 M | -107,98 M | -246,49 M | -64,49 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 49,06 M | 64,60 M | 145,86 M | 172,92 M | 141,89 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 4,13 M | 5,47 M | 6,24 M | 6,63 M | 5,95 M |
| Interest Expense | 0,0 | 0,0 | 13,18 M | 6,02 M | 2,91 M |
| Income Tax | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 138,19 M | 139,81 M | 358,60 M | 348,78 M | 354,86 M |
| Total Liabilities | 93,98 M | 126,03 M | 403,46 M | 338,00 M | 223,35 M |
| Shareholders' Equity | 44,22 M | 13,78 M | -44,86 M | 10,78 M | 131,51 M |
| Total Debt | — | — | 110,00 M | 50,00 M | 24,05 M |
| Cash & Equivalents | 45,77 M | 30,79 M | 127,97 M | 163,03 M | 180,00 M |
| Current Assets | 49,38 M | 38,67 M | 175,41 M | 194,76 M | 303,63 M |
| Current Liabilities | 19,32 M | 41,22 M | 98,66 M | 85,60 M | 82,26 M |
Sectorvergelijking
vs Manufacturing sector mediaan (1605 peers)
Vergeleken met vergelijkbare bedrijven in Manufacturing
Sectorvergelijking
vs Manufacturing sector mediaan (1605 peers) Vergeleken met vergelijkbare bedrijven in Manufacturing| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 14,9 | -1,5 |
| P/B | 1,9 | 1,6 |
| ROE % | 14,9 | -54,7 |
| Net Margin % | 721,9 | -41,5 |
| Rev Growth 5Y % | -72,8 | 1,7 |
| D/E | — | 0,3 |
ETFs Holding This Stock
ETFs Holding This Stock
BRSIX
BRSIX
0,18% weight
{"event":"ticker_viewed","properties":{"ticker":"MCRB","listing_kind":"stock","pathname":"/stocks/mcrb","exchange":"NASDAQ","country":"US"}}